Want to see HK:6660 full AI Analyst Report?
AIM Vaccine Co., Ltd. Class H (6660) AI Stock Analysis
AIM Vaccine Co., Ltd. Class H
(HKEX:6660)
Low score driven primarily by weak financial performance with declining revenue, sustained losses, and rising leverage. Unfavorable valuation from negative P/E adds pressure, while technical indicators offer only limited offsetting support from short-term trends.
AIM Vaccine Co., Ltd. Class H (6660) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.88B
- Dividend Yield
- ―
- Average Volume (3M)
- 265.50K
- Price to Earnings (P/E)
- -2.4
- Beta (1Y)
- 1.24
- Revenue Growth
- -18.45%
- EPS Growth
- -151.15%
- Country
- Hong Kong
- Employees
- 1,466
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
AIM Vaccine Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Operating within the People's Republic of China, AIM Vaccine Co., Ltd. specializes in the entire lifecycle of human vaccine products, encompassing their discovery, production, and market introduction. Among its current developments, the company is ad...
AIM Vaccine Co., Ltd. Class H Financial Statement Overview
Summary
Weak income statement with declining revenue and persistent net losses, mixed balance sheet with rising debt and falling equity, and poor cash flow due to ongoing negative free cash flow.
Income Statement
25NegativeBalance Sheet
45NeutralCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 996.81M | 1.15B | 1.29B | 1.19B | 1.26B | 1.57B |
| Gross Profit | 648.28M | 760.20M | 953.51M | -611.21M | 1.03B | 1.29B |
| EBITDA | -32.42M | -49.54M | -57.89M | -2.05B | -242.03M | -451.71M |
| Net Income | -665.47M | -675.46M | -277.23M | -1.30B | -319.60M | -692.77M |
Balance Sheet | ||||||
| Total Assets | 6.33B | 6.55B | 7.31B | 7.26B | 8.88B | 8.07B |
| Cash, Cash Equivalents and Short-Term Investments | 193.15M | 384.72M | 594.87M | 736.41M | 818.91M | 746.74M |
| Total Debt | 1.77B | 1.76B | 1.84B | 1.80B | 1.40B | 650.43M |
| Total Liabilities | 3.53B | 3.61B | 3.70B | 3.37B | 3.01B | 2.37B |
| Stockholders Equity | 2.64B | 2.76B | 3.37B | 3.64B | 4.96B | 4.89B |
Cash Flow | ||||||
| Free Cash Flow | -95.56M | -171.39M | -139.09M | -467.14M | -966.96M | -1.05B |
| Operating Cash Flow | 116.22M | 67.47M | 99.19M | -165.50M | -110.32M | 93.40M |
| Investing Cash Flow | -66.37M | -107.73M | -162.34M | -271.96M | -858.15M | -1.34B |
| Financing Cash Flow | -185.62M | -111.65M | -26.22M | 362.07M | 980.37M | 788.02M |
AIM Vaccine Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6660, the sentiment is Negative. The current price of 1.53 is below the 20-day moving average (MA) of 1.63, below the 50-day MA of 1.67, and below the 200-day MA of 2.28, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 43.23 is Neutral, neither overbought nor oversold. The STOCH value of 34.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6660.
AIM Vaccine Co., Ltd. Class H Peers Comparison
Overall Rating
HK:226981Outperform
HK:154871Outperform
HK:375953Neutral
HK:213742Neutral- HK:666040Underperform
HK:219739Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2269 | 81Outperform | HKD 183.11B | 31.13 | 10.51% | ― | 21.93% | 21.94% |
| HK:1548 | 71Outperform | HKD 79.58B | -14.95 | -16.23% | ― | 53.48% | -120.02% |
| HK:3759 | 53Neutral | HKD 80.45B | 41.79 | 10.93% | 0.85% | 24.21% | 19.72% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2137 | 42Neutral | HKD 708.65M | -3.48 | -7.32% | ― | ― | 51.71% |
| HK:6660 | 40Underperform | HKD 1.88B | -2.43 | -24.66% | ― | -18.45% | -151.15% |
| HK:2197 | 39Underperform | HKD 1.62B | 1.60 | -64.89% | ― | -99.15% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6660 | AIM Vaccine Co., Ltd. Class H | 1.53 | -2.33 | -60.23% | |
| HK:1548 | Genscript Biotech Corporation | 35.02 | 17.98 | 105.52% | |
| HK:2269 | Wuxi Biologics (Cayman) | 44.48 | 8.86 | 24.87% | |
| HK:2137 | Brii Biosciences Limited | 0.98 | -0.91 | -48.15% | |
| HK:3759 | Pharmaron Beijing Co., Ltd. Class H | 26.98 | 1.65 | 6.50% | |
| HK:2197 | Clover Biopharmaceuticals Ltd. | 1.25 | -0.99 | -44.20% |
AIM Vaccine Co., Ltd. Class H Corporate Events
AIM Vaccine Delays EGM to Revise Domestic Unlisted Share Issuance Plan
AIM Vaccine Co., Ltd. has adjourned its second extraordinary general meeting originally scheduled for September 7, 2026, as the board is considering amendments to its issuance plan for domestic unlisted shares under a specific mandate. The company sa...
AIM Vaccine Seeks Approval for High-Potency Human Diploid Cell Rabies Shot
AIM Vaccine Co., Ltd. has submitted an application to China’s National Medical Products Administration for marketing registration of its independently developed iterative high-potency human diploid cell rabies vaccine. Phase III trial results s...
AIM Vaccine Interim Revenue Slides as Losses Narrow Slightly
AIM Vaccine Co., Ltd., a mainland Chinese biopharmaceutical group listed in Hong Kong, specializes in developing, manufacturing and selling human vaccines. It targets healthcare providers and public health markets, competing on product portfolio and...
AIM Vaccine Revises Domestic Share Issuance and Secures Key Subscriptions
AIM Vaccine has approved amendments to its previously authorized issuance of domestic unlisted shares, expanding the range from not less than 40 million to not more than 80 million shares and fixing the issue price at RMB1.07 per share. The revised p...
AIM Vaccine Seeks Shareholder Nod for Private Domestic Share Issue and Dual Mainland Listings
AIM Vaccine Co., Ltd., a Hong Kong-listed biopharmaceutical company focused on vaccine development and commercialization, plans to broaden its capital market presence by listing its domestic unlisted shares on the National Equities Exchange and Quota...
AIM Vaccine Sets August Board Meeting to Approve Interim Results and Consider Dividend
AIM Vaccine Co., Ltd., a PRC-based biopharmaceutical company listed in Hong Kong, specializes in vaccine development and manufacturing for public health needs and is governed by a board comprising executive, non-executive and independent non-executiv...
AIM Vaccine Advances Serum-Free Rabies Shot Toward China Market Approval
AIM Vaccine’s wholly owned subsidiary AIM Rongyu has completed submission of supplementary data to China’s National Medical Products Administration for market registration of its self-developed serum-free iterative rabies vaccine, followi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 28, 2026